LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Closed

SectorHealthcare

1.36 3.03

Buy Sell

Overview

Share price change

24h

Current

Min

1.32

Max

1.3900000000000001

Key metrics
By Trading Economics
Income	1.8M -32M
Sales	-166K 1.7M
Profit margin	-1,852.384
Employees	181
EBITDA	7.9M -29M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+280% upside

Dividends
By Dow Jones
Next Earnings	3 mar 2026

Market Stats
By TradingEconomics
Market Cap	18M 144M
Previous open	-1.67
Previous close	1.36

News Sentiment

By Acuity

50%

165 / 351 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

0.9101 / 1.14 Support & Resistance

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

18 lut 2026, 22:31 UTC

Earnings

Brambles Raises Dividend, Cash-Flow Guidance as 1st Half Profit Jumps -- Update

18 lut 2026, 22:18 UTC

Earnings

Wal-Mart de Mexico 4Q Profit Falls, Hit by Higher Taxes

18 lut 2026, 22:11 UTC

Earnings

Wesfarmers Boosts Dividend After 1st Half Profit Rises -- Update

18 lut 2026, 21:52 UTC

Earnings

Telstra Boosts Dividend as First-Half Earnings Rise 5.5% -- Update

18 lut 2026, 23:56 UTC

Market Talk

Santos's Review of Domestic Assets Could Lead to Simpler Portfolio -- Market Talk

18 lut 2026, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18 lut 2026, 23:46 UTC

Market Talk

Nikkei May Rise After U.S. Tech Stock Gains -- Market Talk

18 lut 2026, 23:34 UTC

Market Talk

Earnings

Brambles' Cost Control Stands Out to Bull -- Market Talk

18 lut 2026, 23:33 UTC

Market Talk

Gold Edges Higher Amid Growing Risks of U.S.-Iran Conflict -- Market Talk

18 lut 2026, 23:32 UTC

Market Talk

Australia Jobs Data Will Likely Support May Hike Assumptions -- Market Talk

18 lut 2026, 22:45 UTC

Earnings

DoorDash Stock Rebounds. Earnings and Revenue Both Fall Short. -- Barrons.com

18 lut 2026, 22:44 UTC

Market Talk

Investors Eyeing Nvidia's Revenue Visibility Ahead of 4Q Print -- Market Talk

18 lut 2026, 22:37 UTC

Earnings

Nutrien 4Q EPS $1.18 >NTR.T

18 lut 2026, 22:37 UTC

Earnings

Nutrien 4Q Sales $5.34B >NTR.T

18 lut 2026, 22:35 UTC

Earnings

Pan American Silver 4Q EPS $1.07 >PAAS

18 lut 2026, 22:35 UTC

Earnings

Pan American Silver 4Q Rev $1.18B >PAAS

18 lut 2026, 22:30 UTC

Earnings

Kinross Gold Raises Quarterly Dividend to 4c Vs. 3.5c >K.T

18 lut 2026, 22:29 UTC

Earnings

Kinross Gold 4Q EPS 75c >K.T

18 lut 2026, 22:22 UTC

Earnings

Coeur Mining: Full-Yr 2026 Production Is Expected to Be 55,000 - 65,000 Ounces of Gold and 5.5M - 6.3M Ounces of Silver >CDE

18 lut 2026, 22:22 UTC

Market Talk

Nvidia 4Q Earnings Coming Amid China Export Battle -- Market Talk

18 lut 2026, 22:16 UTC

Earnings

Brambles Raises Dividend, Cash-Flow Guidance as 1H Profit Jumps -- Update

18 lut 2026, 22:05 UTC

Earnings

Pan American Silver Reports Record Fourth Quarter And Full Year 2025 Financial Results; Record Cash Flow From Operations Of $554 Million In The Fourth Quarter; Dividend Increased By 29% >PAAS

18 lut 2026, 22:03 UTC

Earnings

Kaiser Aluminum Expects to Improve Conversion Rev by 5% to 10% and Adj EBITDA by 5% to 15% for FY26 >KALU

18 lut 2026, 22:02 UTC

Earnings

Kaiser Aluminum 4Q Adj EPS $1.53 >KALU

18 lut 2026, 22:02 UTC

Earnings

Kaiser Aluminum 4Q Sales $929M >KALU

18 lut 2026, 22:02 UTC

Earnings

Kaiser Aluminum 4Q EPS $1.68 >KALU

18 lut 2026, 22:00 UTC

Earnings

Kinross Gold 4Q Adj EPS 67c >KGC

18 lut 2026, 22:00 UTC

Earnings

Kinross Gold 4Q Sales $2.02B >KGC

18 lut 2026, 21:56 UTC

Earnings

Wesfarmers Boosts Dividend After 1H Profit Rises -- Update

18 lut 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

280% upside

12 Months Forecast

Average 4.75 USD 280%

High 7 USD

Low 2.5 USD

Based on 2 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

Buy

Hold

Sell

Based on 2 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

165 / 351 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.